Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$49.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Merrimack Pharmaceuticals Inc announces encouraging clinical data from expanded phase one study of MM-302 for the treatment of advanced her2-positive breast cancer


Friday, 13 Dec 2013 08:30am EST 

Merrimack Pharmaceuticals Inc:Says Phase one clinical trial results for MM-302, a HER2-targeted liposomal doxorubicin for the treatment of advanced HER2-positive breast cancer.Says the Primary objectives for the trial are to assess the safety of MM-302 as a monotherapy and in combination with trastuzumab, as well as to determine the Phase two dose for MM-302. Data were presented at the 2013 San Antonio Breast Cancer Symposium, Dec. 10-14, 2013 in San Antonio, Texas.Says Anthracyclines, particularly doxorubicin, have been an effective component of breast cancer treatment for decades, though their use is ultimately limited by cardiac toxicity.Says In this ongoing Phase one study, patients treated with MM-302 showed no signs of clinical decline in cardiac function.Says a Phase 2 study for MM-302 is being planned in patients with HER2-positive breast cancer. 

Company Quote

11.78
0.06 +0.51%
4 Mar 2015